NEW YORK, Feb. 3, 2017 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it is continuing to investigate potential securities claims on behalf of shareholders of Psychemedics Corporation (NASDAQ: PMD) resulting from allegations that Psychemedics may have issued materially misleading business information to the investing public.
On January 31, 2017, it was announced that Psychemedics Corporation's local representative in Brazil, Psychemedics Brasil Exames Toxicologicos Ltda., was ordered on January 20, 2017 to compensate Omega Laboratories, Inc. USA for losses caused by anticompetitive practices used for the purpose of "preventing other companies from accessing (the) market." On this news, shares of Psychemedics fell $6.75 per share or over 26% to close at $18.87 per share on January 31, 2017.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Psychemedics investors. If you purchased shares of Psychemedics on or before January 30, 2017, please visit the firm's website at http://www.rosenlegal.com/cases-1047.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com
SOURCE Rosen Law Firm, P.A.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article